AMPH Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 20.35% compared to Amphastar Pharmaceuticals's net margin of 16.72%. Amphastar Pharmaceuticals's return on equity of 22.89% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Amphastar Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 37.03%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.72 which suggests that it could grow by 34.36%. Given that Amphastar Pharmaceuticals has higher upside potential than Biomarin Pharmaceutical, analysts believe Amphastar Pharmaceuticals is more attractive than Biomarin Pharmaceutical.

Amphastar Pharmaceuticals has a beta of 0.768, which suggesting that the stock is 23.238% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $186.5M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Amphastar Pharmaceuticals's net income of $38M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 9.30x while Biomarin Pharmaceutical's PE ratio is 32.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.02x versus 5.01x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 20.35% compared to Amphastar Pharmaceuticals's net margin of 32.59%. Amphastar Pharmaceuticals's return on equity of 22.89% beat Eli Lilly and's return on equity of 80.24%.

Amphastar Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 37.03%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 16.83%. Given that Amphastar Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Amphastar Pharmaceuticals is more attractive than Eli Lilly and.

Amphastar Pharmaceuticals has a beta of 0.768, which suggesting that the stock is 23.238% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.62% to investors and pays a quarterly dividend of $1.50 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amphastar Pharmaceuticals quarterly revenues are $186.5M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Amphastar Pharmaceuticals's net income of $38M is lower than Eli Lilly and's net income of $4.4B. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 9.30x while Eli Lilly and's PE ratio is 73.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.02x versus 17.36x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Viemed Healthcare has a net margin of 20.35% compared to Amphastar Pharmaceuticals's net margin of 7.11%. Amphastar Pharmaceuticals's return on equity of 22.89% beat Viemed Healthcare's return on equity of 9.21%.

Amphastar Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 37.03%. On the other hand Viemed Healthcare has an analysts' consensus of $12.83 which suggests that it could grow by 77.26%. Given that Viemed Healthcare has higher upside potential than Amphastar Pharmaceuticals, analysts believe Viemed Healthcare is more attractive than Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals has a beta of 0.768, which suggesting that the stock is 23.238% less volatile than S&P 500. In comparison Viemed Healthcare has a beta of 1.504, suggesting its more volatile than the S&P 500 by 50.437%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Viemed Healthcare pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $186.5M, which are larger than Viemed Healthcare quarterly revenues of $60.7M. Amphastar Pharmaceuticals's net income of $38M is higher than Viemed Healthcare's net income of $4.3M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 9.30x while Viemed Healthcare's PE ratio is 25.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.02x versus 1.32x for Viemed Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of 20.35% compared to Amphastar Pharmaceuticals's net margin of -14.64%. Amphastar Pharmaceuticals's return on equity of 22.89% beat Viatris's return on equity of -3.22%.

Amphastar Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 37.03%. On the other hand Viatris has an analysts' consensus of $11.7625 which suggests that it could grow by 28.55%. Given that Amphastar Pharmaceuticals has higher upside potential than Viatris, analysts believe Amphastar Pharmaceuticals is more attractive than Viatris.

Amphastar Pharmaceuticals has a beta of 0.768, which suggesting that the stock is 23.238% less volatile than S&P 500. In comparison Viatris has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.819%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.25% to investors and pays a quarterly dividend of $0.12 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $186.5M, which are smaller than Viatris quarterly revenues of $3.5B. Amphastar Pharmaceuticals's net income of $38M is higher than Viatris's net income of -$516.5M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 9.30x while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.02x versus 0.74x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.